Here are some considerations to keep in mind: Efficacy Concerns : There is limited research on the effectiveness of microdosing GLP-1 medications
Discussion In this study, we used a de-identified patient EHR database to analyze the real-world response of T2D patients to GLP-1 M treatment and to predict which patients might benefit most from this class of T2D medications
As GLP-1 and GLP-2 have become important targets in the treatment of type 2 diabetes, obesity and malabsorptive conditions 16,17,62 , we therefore characterized gut microbiome signatures in DIO mice treated with liraglutide, a selective GLP-1 receptor agonist, or GUB09-145, a potent dual GLP-1/GLP-2 agonist 26
2.3 Statistical Analyses of the Clinical Study SAS version 9.4 (SAS Institute, Cary, NC, USA) was used to conduct the statistical analyses
While linear interpolation provides reasonable estimates for visualization purposes, actual weight loss may not follow perfectly linear trajectories between anchor points